13 Mar 2025
By David Wild
Key Takeaways
- BPGbio’s biology-first approach to AI drug discovery has yielded promising clinical results in hard-to-treat cancers.
- Targeting E2 enzymes rather than E3 ligases could be a breakthrough approach for protein degradation therapies.
- BPGbio’s real-time use of clinical data and causal AI models enables more precise patient selection and optimized trial design.
From the article:
Biotech BPGbio applies causal AI to generate insights from samples from what the CEO says is one of the world’s largest biobanks. With several promising late-stage programs, its platform seems to be yielding fruit.
In an industry enamored with artificial intelligence breakthroughs, BPGbio stands apart with a refreshingly pragmatic approach.
“At the end of the day, when someone’s lying in a hospital bed, they don’t give a sh*t about the algorithms. They want a drug to save them,” CEO Niven Narain stated bluntly in an interview with In Vivo. This focus on tangible outcomes rather than technological showmanship has quietly positioned BPGbio as an intriguing biopharma innovator.
Full article (possible paywall): BPGbio: Fusing Patient-Driven Innovation With Causal AI
